After losing some value lately, a hammer chart pattern has been formed for Allarity Therapeutics, In

Evogene (NASDAQ: EVGN - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report)

Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) and Autolus Therapeutics (NASDAQ: AUTL - Get

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 c

- Recently awarded patents have solidified Allarity's strategy to leverage DRP to ensure the commerc

- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib- New p

- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New

Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get F

Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several sma

Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with severa

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy an

TARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”)

TARPON SPRINGS, Fla., September 11, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”)

Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which beat the an

- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, pr

Here is how Allarity Therapeutics, Inc. (ALLR) and ANIXA BIOSCIENCES INC (ANIX) have performed compa

Allarity Therapeutics is now poised to run its DRP® testing in-house in a CLIA-certified laboratory

Allarity Therapeutics is now poised to run its DRP ® testing in-house in a CLIA-certified laboratory

Here is how Allarity Therapeutics, Inc. (ALLR) and Amgen (AMGN) have performed compared to their sec

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2

Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP ® until A

Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript

Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market

Here is how Allarity Therapeutics, Inc. (ALLR) and Alterity Therapeutics Limited - Sponsored ADR (AT

The poster outlines the scientific background, study design, and clinical rationale for the Company&

Principal Investigator Kathleen N. Moore, M.D.

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy an

Here is how Allarity Therapeutics, Inc. (ALLR) and Bioventus (BVS) have performed compared to their

Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.17) per share which beat the an

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast T

TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDA

U.S. stock futures were swinging between gains and losses on Tuesday after a mixed session on Monday

Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares rose sharply during today’s pre-market

Shares of Reliance Global Group, Inc. (NASDAQ: RELI) fell sharply in today’s pre-market trading af

Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second

Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarte

  On Thursday, 369 companies hit new 52-week lows.

  On Wednesday, 311 stocks hit new 52-week lows.